drugset / Trial / NCT02394314

A Phase 1, Single Dose Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Healthy Volunteers

NCT02394314

Phase 1 Completed 362 enrolled MedImmune LLC
RandomizedSingle-groupDouble-blindTreatment

Summary

A Phase 1, single dose study with 8 cohorts of ascending doses designed to evaluate the safety and pharmacokinetics of MEDI0382 in healthy volunteers.

Timeline

Start
2015-02
Primary completion
2015-08
Completion
2015-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Cotadutide Peptide Subcutaneous

Indications

No indication recorded.